Back

A spatial atlas of chemoradiation therapy in pancreatic cancer identifies cellular and microenvironmental determinants of persister populations

Bernard, V.; Ku, L.-T.; Wang, T.; Acevedo-Diaz, A.; Rajapakshe, K. I.; Jacobson, G.; Tovar, D.; Min, J.; Pei, G.; Tat, C.; Suresh, A.; Tzeng, C.-W. D.; Katz, M. H.; Bhutani, M. S.; Wang, H.; Wolff, R. A.; Haymaker, C.; Ludmir, E. B.; Huang, H.; Chen, X.; Li, L.; Koong, A. C.; Wang, L.; Navin, N. E.; Jiang, D.; Li, Z.; Maitra, A.; Koay, E. J.

2025-06-25 cancer biology
10.1101/2025.06.20.660757 bioRxiv
Show abstract

The molecular pathways involved in the response to radiation therapy in pancreatic ductal adenocarcinoma (PDAC) remain poorly understood. We aimed to elucidate the adaptive mechanisms and cellular interactions within PDAC to radiation therapy (RT). We constructed a transcriptomic landscape of the cellular subtypes and spatially resolved neighborhoods from 50 patient samples, including 16 longitudinally matched single cell RNA sequencing and 34 spatial transcriptomics specimens. To resolve shortcomings of cell-type mixtures in spatial data, we developed a novel statistical method called SpaCCI (spatially aware analysis of cell-cell interactions) to profile cell-cell interactions and ligand-receptor enrichment. This revealed CXCL12/TGF{beta}-driven persister cell niches where activated fibroblasts reprogram tumor- associated macrophages and spatially exclude stress-response CD8 T cells after RT. Persister cancer cells displayed transcriptional evidence of recalcitrance to metal-induced cell death pathways of ferroptosis and cuproptosis which were recapitulated in preclinical models. Our study reveals the selective pressures experienced by PDAC following RT that may help provide insight for future multimodal therapeutic strategies.

Matching journals

The top 5 journals account for 50% of the predicted probability mass.

1
Cancer Research
130 papers in training set
Top 0.1%
18.7%
2
Nature Communications
5641 papers in training set
Top 8%
18.7%
3
Nature Cancer
39 papers in training set
Top 0.1%
6.8%
4
Cancer Discovery
66 papers in training set
Top 0.4%
5.5%
5
npj Precision Oncology
53 papers in training set
Top 0.4%
3.5%
50% of probability mass above
6
Genome Medicine
183 papers in training set
Top 1%
3.3%
7
eLife
5828 papers in training set
Top 33%
3.3%
8
Science Advances
1243 papers in training set
Top 10%
3.3%
9
Cell Reports
1498 papers in training set
Top 14%
2.8%
10
Cancer Research Communications
51 papers in training set
Top 0.5%
2.7%
11
Cancer Cell
42 papers in training set
Top 0.5%
2.5%
12
Cell Reports Medicine
153 papers in training set
Top 1%
2.5%
13
Communications Biology
993 papers in training set
Top 10%
2.1%
14
Clinical Cancer Research
64 papers in training set
Top 1%
1.7%
15
Genome Biology
637 papers in training set
Top 5%
1.7%
16
Nature Genetics
286 papers in training set
Top 3%
1.4%
17
Journal for ImmunoTherapy of Cancer
75 papers in training set
Top 1%
1.1%
18
Scientific Reports
3612 papers in training set
Top 70%
1.0%
19
Nature Cell Biology
118 papers in training set
Top 3%
0.9%
20
Molecular Cancer Research
49 papers in training set
Top 1%
0.9%
21
Proceedings of the National Academy of Sciences
2444 papers in training set
Top 41%
0.9%
22
Journal of Clinical Investigation
179 papers in training set
Top 6%
0.6%
23
Nature Biotechnology
172 papers in training set
Top 5%
0.6%